结核病平台临床试验中细菌负荷与疗效评估潜在生物标志物的系统综述
该研究系统综述了成人结核病治疗疗效生物标志物,按平台试验开发阶段分为α、β、γ三类,共纳入86项研究、22864名参与者;从1356个生物标志物条目中,318个报告了目标性能指标,其中103个为有前景的预测指标、41个为良好预测指标。
要点
- α类(2a期细菌负荷):痰分枝杆菌RNA、脂阿拉伯甘露聚糖(LAM)及尿宿主代谢物有前景。
- β类(2b-c期早期/治疗终点):分枝杆菌RNA及宿主转录组或细胞因子特征可用于早期治疗反应。
- γ类(2c-3期治疗后/试验水平):宿主转录组学可用于复发预测。
核心结论
- 不同类别生物标志物的组合可能有助于设计更高效的平台试验。
- 开发疗效替代指标的工作应更好地协调。
研究设计与样本
- 系统综述,纳入成人结核病治疗疗效生物标志物相关研究,共86项研究、22864名参与者。
- 将生物标志物按平台试验开发阶段分为α、β、γ三类,分析单元为生物标志物、预测结局及测量时间或间隔的组合。
主要发现
- 从1356个生物标志物条目中,318个报告了目标性能指标,其中103个为有前景的预测指标、41个为良好预测指标。
- α类:痰分枝杆菌RNA和脂阿拉伯甘露聚糖(LAM)及尿宿主代谢物。
- β类:分枝杆菌RNA及宿主转录组或细胞因子特征用于早期治疗反应。
- γ类:宿主转录组学用于复发预测。
关键数值与推荐
- 性能指标包括灵敏度、特异度、受试者工作特征曲线下面积(AUC)及相关性指标,分类为差、有前景或良好。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adaptive platform trials can be more efficient than classic trials for developing new treatments. Moving from culture-based to simpler- or faster-to-measure biomarkers as efficacy surrogates may enhance this advantage. We performed a systematic review of treatment efficacy biomarkers in adults with tuberculosis. Platform trials can span different development phases. We grouped biomarkers as: α, bacterial load estimates used in phase 2a trials; β, early and end-of treatment end points, phase 2b-c trials; γ, posttreatment or trial-level estimates, phase 2c-3 trials. We considered as analysis unit (biomarker entry) each combination of biomarker, predicted outcome, and their respective measurement times or intervals. Performance metrics included: sensitivity, specificity, area under the receiver-operator curve (AUC), and correlation measures, and classified as poor, promising, or good. Eighty-six studies included 22 864 participants. From 1356 biomarker entries, 318 were reported with the performance metrics of interest, with 103 promising and 41 good predictors. Group results were: α, mycobacterial RNA and lipoarabinomannan (LAM) in sputum, and host metabolites in urine; β, mycobacterial RNA and host transcriptomic or cytokine signatures for early treatment response; and γ, host transcriptomics for recurrence. A combination of biomarkers from different categories could help in designing more efficient platform trials. Efforts to develop efficacy surrogates should be better coordinated.
引用
- Espinosa-Pereiro J, Alagna R, Saluzzo F, et al. A Systematic Review of Potential Biomarkers for Bacterial Burden and Treatment Efficacy Assessment in Tuberculosis Platform-Based Clinical Trials. J Infect Dis. 2024. PMID: 37956107. doi:10.1093/infdis/jiad482
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。